Program Type: Midwest CEPAC

Pulmonary Arterial Hypertension

Dec 2023 | Assessment

Interventions of Interest: For questions please contact Yamaya Jean, Program Manager, at yjean@icer.org. View the Key Stakeholder List.

Non-Alcoholic Steatohepatitis

Apr 2023 | Assessment

Interventions of Interest: An independent appraisal committee narrowly voted that currently available evidence for resmetirom is adequate to demonstrate a net health benefit over lifestyle management, whereas current evidence for obeticholic acid was deemed inadequate to demonstrate a net health benefit. ICER analyses suggest resmetirom would achieve common thresholds for cost-effectiveness if priced between $39,600 – $50,100 […]

Menopause: Vasomotor Symptoms

Dec 2022 | Assessment

Interventions of Interest: The independent appraisal committee voted that evidence is not yet adequate to demonstrate a net health benefit for fezolinetant when compared to no pharmacological treatment. Using point estimates from short-term clinical trials, analyses suggest this drug would achieve common thresholds for cost-effectiveness if priced between $2,000 – $2,600 per year for women […]

Amyotrophic Lateral Sclerosis (ALS)

Aug 2022 | Assessment

Interventions of Interest: AMX0035 (RELYVRIO™, Amylyx Pharmaceuticals, Inc.) oral edaravone (Mitsubishi Tanabe Pharma Development America, Inc.) The majority of independent appraisal committee voted that the evidence is adequate to demonstrate that both AMX0035 and oral edaravone (in population narrower than its label) provide a net health benefit compared to standard of care. They also determined […]

COVID-19

Dec 2022 | Assessment

Interventions of Interest: We have deemed this a “special assessment” since this is an early snapshot of emerging agents in the COVID-19 pipeline. December 2022 Update Dominant viral variants, vaccination/prior infection status, and evidence on Paxlovid continue to evolve, but ICER is presenting an update based on recent evidence to help inform new discussions on […]

Asthma

Nov 2021 | Assessment

Interventions of Interest: ICER’s Evidence Report Findings: Tezepelumab reduces asthma exacerbations, but there is uncertainty about long-term safety as with all new biologic therapies; tezepelumab would achieve common thresholds for cost-effectiveness if priced between $9,000 – $12,100 per year. Recommendations for fair access include ensuring that all biologic options be available for patients with severe […]

Multiple Myeloma

Apr 2021 | Assessment

Interventions of Interest: The Midwest CEPAC unanimously determined the evidence is adequate to demonstrate that CAR-T treatments ide-cel and cilta-cel both provide a net health benefit when compared to usual care; despite these benefits, for ide-cel, the only CAR-T agent having received FDA approval at this time, a majority of panelists voted that it represents […]